Does Medicare Cover Wegovy in 2026?
Short answer: only for established cardiovascular disease, not for weight loss alone. Federal law has excluded weight-loss drugs from Medicare since 2003 and that hasn't changed. The 2024 expansion gave Medicare patients with documented ASCVD a path to Wegovy at Part D copay rates (often $30–$100/month after deductible). Without ASCVD, you're looking at NovoCare self-pay around $499/month or branded telehealth around $449/month. Below: what counts as CVD, why the savings card is off-limits, and the cleanest cash-pay alternatives.
Wegovy on Medicare: who pays what
| Your situation | Typical monthly cost |
|---|---|
| Medicare + ASCVD + plan covers Wegovy + Extra Help | $0–$11 |
| Medicare + ASCVD + plan covers Wegovy | $30–$100 |
| Medicare + no ASCVD (cash-pay floor) | $499 |
| Medicare + telehealth Wegovy | $449 |
| Cash retail (full WAC) | $1,349 |
Why Medicare excludes weight-loss drugs (the 2003 law that's still in force)
The Medicare Modernization Act of 2003, which created Part D, explicitly excluded from coverage "agents when used for anorexia, weight loss, or weight gain." That language is still on the books in May 2026. There have been multiple legislative efforts (notably the Treat and Reduce Obesity Act, TROA) to repeal the exclusion, but none have passed. So when a Medicare patient asks a pharmacy "does Medicare cover Wegovy for weight loss," the technical answer is no, by statute.
The 2024 cardiovascular expansion did not change the underlying statute. Instead, the FDA expanded Wegovy's label to include cardiovascular risk reduction, and CMS clarified that Part D plans can cover Wegovy for that indication — because it's no longer being used for weight loss alone.
What counts as ASCVD for the cardiovascular indication
The FDA label requires "established cardiovascular disease" in adults with overweight or obesity. In practice this means one of:
- Prior myocardial infarction (heart attack)
- Prior ischemic stroke
- Established coronary artery disease (e.g. prior catheterization showing stenosis)
- Prior peripheral arterial disease with documented vascular involvement
- Prior coronary or peripheral revascularization (stent, bypass, angioplasty)
What does NOT qualify on its own: hypertension, high cholesterol, family history of heart disease, prediabetes, or high CVD risk score without documented disease. Your prescriber needs the ICD-10 code for the qualifying condition on your chart before running the prior auth.
If you don't qualify: NovoCare self-pay (~$499/mo)
NovoCare's self-pay reference price is the cheapest legitimate path for Medicare patients who don't meet the CVD indication. Unlike the Wegovy Savings Card, NovoCare self-pay is NOT a copay-assistance program — it's a direct-to-patient pricing tier from Novo Nordisk that Medicare beneficiaries can access. As of May 2026, the reference price is approximately $499/month.
Apply at novocare.com.
Visit NovoCare →Should you switch to Zepbound on Medicare?
Generally not for the Medicare-coverage question specifically. Zepbound has no analogous CVD label expansion as of May 2026, so Medicare Part D will not cover it for cardiovascular indication the way they cover Wegovy. The Zepbound Savings Card is also excluded for Medicare patients by the same federal anti-kickback rules.
What Medicare patients CAN do with Zepbound: pay cash via Eli Lilly's LillyDirect self-pay vials (around $349/month for the lower doses), which is not a copay-assistance program and is open to Medicare beneficiaries. Read more at How to Get Zepbound Without Insurance.
Cash-pay alternatives if Medicare denies Wegovy
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $499 | $449 | $249 cheapest | $1,349 | Get → |
| Ozempic 11.6% weight loss | $63 | — | $399 | $199 cheapest | $998 | Get → |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $499 | $449 cheapest | — | $1,349 | Get → |
| Zepbound 22.5% weight loss | $88 | $349 | $499 | $299 cheapest | $1,059 | Get → |
| Mounjaro 20.9% weight loss | $88 | — | $499 | $299 cheapest | $1,069 | Get → |
| Saxenda 8.4% weight loss | $63 | — | $399 cheapest | — | $1,349 | Get → |
Frequently asked questions
Does Medicare cover Wegovy for weight loss?
No — not for weight loss as the sole indication. Federal law (the Medicare Modernization Act of 2003) explicitly excludes "drugs when used for anorexia, weight loss, or weight gain" from Medicare Part D, and that statute is still in effect in May 2026. The only exception is when a GLP-1 is FDA-approved for a non-weight-loss indication that the patient also has — for Wegovy, that means cardiovascular disease.
When does Medicare cover Wegovy?
Since March 2024, Medicare Part D plans can cover Wegovy specifically for established cardiovascular disease in adults with overweight or obesity, after the FDA expanded Wegovy's label based on the SELECT trial (Wegovy reduced major adverse cardiovascular events by ~20%). To qualify, you need documented atherosclerotic cardiovascular disease (ASCVD) on your chart — typically meaning a prior heart attack, stroke, or established coronary/peripheral artery disease.
What counts as "established cardiovascular disease" for Medicare Wegovy coverage?
The FDA-approved language is established cardiovascular disease — typically interpreted as: prior myocardial infarction, prior ischemic stroke, prior peripheral arterial disease (e.g. claudication with documented vascular disease), or prior coronary/peripheral revascularization (stent, bypass, etc.). Hypertension, high cholesterol, or family history alone do NOT qualify. You will need ICD-10 codes on your chart documenting the qualifying CVD before your Part D plan will approve.
Does Medicare Advantage cover Wegovy differently than Medicare Part D?
Coverage rules are largely the same — Medicare Advantage plans are required to cover at least everything traditional Medicare + Part D covers, but they administer their own formularies and prior-authorization requirements. Some Medicare Advantage plans cover Wegovy more readily than the strict CVD-indication standard would suggest, especially when the plan considers obesity care a quality measure. Check your specific plan's formulary on its member portal.
Can I use the Wegovy savings card with Medicare?
No. The federal anti-kickback statute prohibits manufacturer copay-assistance programs from being used by patients with government insurance (Medicare, Medicaid, Tricare, VA). The Wegovy Savings Card explicitly excludes Medicare beneficiaries — including those on Medicare Advantage plans — even if you have a secondary commercial policy. This applies to all GLP-1 manufacturer copay programs (NovoCare, LillyDirect Savings Card, Mounjaro Savings Card, etc.).
Can I use NovoCare self-pay if I have Medicare?
Yes — NovoCare's self-pay reference pricing (around $499/month for Wegovy in May 2026) is a separate product from the Savings Card and is NOT excluded by Medicare status. NovoCare self-pay is intended for patients without Wegovy coverage, regardless of whether their other insurance is private, government, or none. If your Part D plan denies Wegovy and you don't qualify on the CVD pathway, NovoCare self-pay is usually the cheapest legitimate path.
What if I have Medicare and qualify for Extra Help / LIS?
Low-Income Subsidy (LIS, also called Extra Help) reduces Part D copays substantially — typically to $0–$11/month for covered drugs in 2026. If your Part D plan covers Wegovy under the CVD pathway and you qualify for full LIS, your out-of-pocket can be near zero. LIS does not, however, help if Wegovy is not on your plan's formulary or the prior auth is denied — in that case the underlying coverage gap matters more than the subsidy.
How do I appeal a Medicare denial for Wegovy?
Medicare appeals follow a five-level process: (1) redetermination by the plan, (2) reconsideration by an independent review entity, (3) Administrative Law Judge hearing, (4) Medicare Appeals Council, (5) federal court. For Wegovy specifically, the most common winnable appeal is documenting ASCVD that wasn't properly captured in the initial PA request — your prescriber should attach hospital discharge summaries, cath reports, or echo findings showing established cardiovascular disease.
See also
- → How to Get Wegovy Without Insurance
- → GLP-1 Prior Authorization Guide — how to win a Medicare appeal
- → GLP-1 Savings Cards (commercial only)
- → Zepbound Medicaid Coverage by State
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.